Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis

Phase 1 open-label clinical trial in LN in U.S. is actively recruiting patients at multiple sites KYV-101 is a novel, fully human anti-CD19 chimeric antigen receptor T-cell therapy designed to deplete B cells, including autoreactive B cells in autoimmune disease patients Lupus nephritis (LN) is a serious complication of lupus; nearly half of adults diagnosed … Read more